Shorepoint Capital Partners’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | $5.25M | Buy |
75,634
+4,389
| +6% | +$305K | 1.19% | 28 |
|
|
2024
Q4 | $6.13M | Buy |
71,245
+454
| +0.6% | +$39.1K | 1.4% | 24 |
|
|
2024
Q3 | $8.43M | Sell |
70,791
-677
| -0.9% | -$80.6K | 1.92% | 11 |
|
|
2024
Q2 | $10.2M | Sell |
71,468
-1,673
| -2% | -$239K | 2.39% | 6 |
|
|
2024
Q1 | $9.39M | Sell |
73,141
-6,259
| -8% | -$804K | 2.3% | 7 |
|
|
2023
Q4 | $8.21M | Sell |
79,400
-2,809
| -3% | -$291K | 2.2% | 7 |
|
|
2023
Q3 | $7.48M | Sell |
82,209
-11,733
| -12% | -$1.07M | 2.19% | 9 |
|
|
2023
Q2 | $7.6M | Buy |
93,942
+2,606
| +3% | +$211K | 2.14% | 11 |
|
|
2023
Q1 | $7.27M | Buy |
91,336
+3,808
| +4% | +$303K | 2.08% | 12 |
|
|
2022
Q4 | $5.92M | Buy |
+87,528
| New | +$5.92M | 1.64% | 19 |
|